Reported 1 day ago
Pfizer's stock rose by 2.1% following its announcement to acquire Metsera for at least $47.50 per share, with potential additional payments bringing the total to $7.2 billion. This move aims to bolster Pfizer's presence in the GLP-1 weight loss drug market after setbacks in its previous drug offerings. However, concerns linger over Pfizer's significant debt and the uncertainty surrounding Metsera's drug candidates, prompting analysts to caution against investing in Pfizer at this time.
Source: YAHOO